Literature DB >> 10508280

An exciting and challenging role for the advanced contrast MR imaging.

W T Yuh.   

Abstract

Mesh：

Substances：

Year:  1999        PMID： 10508280     DOI： 10.1002/(sici)1522-2586(199909)10:3<221::aid-jmri1>3.0.co;2-x

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN： 1053-1807            Impact factor:   4.813


× No keyword cloud information.
  8 in total

1.  Assessment of neovascular permeability in a pancreatic tumor model using dynamic contrast-enhanced (DCE) MRI with contrast agents of different molecular weights.

Authors:  Louke J Delrue; Veerle Casneuf; Nancy Van Damme; Peter Blanckaert; Marc Peeters; Wim P Ceelen; Philippe C O Duyck
Journal:  MAGMA       Date:  2011-05-13       Impact factor: 2.310

2.  Characterizing tumor heterogeneity with functional imaging and quantifying high-risk tumor volume for early prediction of treatment outcome: cervical cancer as a model.

Authors:  Nina A Mayr; Zhibin Huang; Jian Z Wang; Simon S Lo; Joline M Fan; John C Grecula; Steffen Sammet; Christina L Sammet; Guang Jia; Jun Zhang; Michael V Knopp; William T C Yuh
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-12-28       Impact factor: 7.038

3.  Predicting control of primary tumor and survival by DCE MRI during early therapy in cervical cancer.

Authors:  William T C Yuh; Nina A Mayr; David Jarjoura; Dee Wu; John C Grecula; Simon S Lo; Susan M Edwards; Vincent A Magnotta; Steffen Sammet; Hualin Zhang; Joseph F Montebello; Jeffrey Fowler; Michael V Knopp; Jian Z Wang
Journal:  Invest Radiol       Date:  2009-06       Impact factor: 6.016

4.  Ultra-early predictive assay for treatment failure using functional magnetic resonance imaging and clinical prognostic parameters in cervical cancer.

Authors:  Nina A Mayr; William T C Yuh; David Jajoura; Jian Z Wang; Simon S Lo; Joseph F Montebello; Kyle Porter; Dongqing Zhang; D Scott McMeekin; John M Buatti
Journal:  Cancer       Date:  2010-02-15       Impact factor: 6.860

5.  Validation of optimal DCE-MRI perfusion threshold to classify at-risk tumor imaging voxels in heterogeneous cervical cancer for outcome prediction.

Authors:  Zhibin Huang; Kevin A Yuh; Simon S Lo; John C Grecula; Steffen Sammet; Christina L Sammet; Guang Jia; Michael V Knopp; Qiang Wu; Norman J Beauchamp; William T C Yuh; Roy Wang; Nina A Mayr
Journal:  Magn Reson Imaging       Date:  2014-08-29       Impact factor: 2.546

6.  Characterizing at-Risk Voxels by Using Perfusion Magnetic Resonance Imaging for Cervical Cancer during Radiotherapy.

Authors:  Zhibin Huang; Nina A Mayr; Simon S Lo; John C Grecula; Jian Z Wang; Guang Jia; William Tc Yuh
Journal:  J Cancer Sci Ther       Date:  2012-09

7.  A simple, reproducible method for monitoring the treatment of tumours using dynamic contrast-enhanced MR imaging.

Authors:  B Morgan; J F Utting; A Higginson; A L Thomas; W P Steward; M A Horsfield
Journal:  Br J Cancer       Date:  2006-05-22       Impact factor: 7.640

8.  Bridging Sunitinib Exposure to Time-to-Tumor Progression in Hepatocellular Carcinoma Patients With Mathematical Modeling of an Angiogenic Biomarker.

Authors:  S Ait-Oudhia; D E Mager; V Pokuri; G Tomaszewski; A Groman; P Zagst; G Fetterly; R Iyer
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-06-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.